Patients in the experimental group will receive two sachets of Glutapak-R every twelve hours for up to six weeks alongside treating physician-chosen EGFR therapy. Patients in the control group will receive a standard-of-care diet.
All patients will receive nutritional counseling every two weeks.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Both sexes
≥ 18 years old
Pathologically confirmed diagnosis of NSCLC
Stage IIIB - IV by the American Joint Committee of Cancer Version 8.
Candidates to receive EGFR-TKI treatment (1st \& 2nd generation TKI)
ECOG score ≤ 2
Life expectancy \> eight weeks
Signed written informed consent
You may not be if
Patients who cannot attend the first protocol appointment.
Treatment with other anti-cancer therapy
Participating in other clinical trials in the former four weeks
Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.
Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.
Active HIV infection.
Breastfeeding.
Clareo Health | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
